Microchip (MCHP) Q2 2027 Earnings Call Transcript

Microchip Technology reported September-quarter net sales of $1.622 billion, up 9.2% sequentially and 42.2% year over year; non-GAAP EPS was $0.97. December-quarter guidance calls for revenue of $1.573 billion-$1.638 billion and non-GAAP EPS of $0.87-$0.95, with gross margin of 64%-65%, as $53 million of September revenue items do not recur and supply constraints limit shipments of high-margin products. Bookings and backlog remained strong, while management cited foundry and OSAT capacity constraints and warned that AI data-center growth could decelerate; industrial, data-center, and aerospace and defense revenue grew 50.3%, 55.7%, and 41% year over year, respectively.

Analysis

The key tension is that MCHP has demand it cannot monetize yet: constrained foundry and OSAT throughput defers high-margin shipments, while supplier price increases can arrive before revenue mix normalizes. This makes backlog a weaker near-term earnings signal than usual. Capacity being qualified or brought in-house may help from next quarter into the June quarter, but qualification and packaging constraints make the recovery uneven; utilization charges and gross margin may therefore lag revenue.

A slowdown in AI infrastructure is not an unambiguous negative for MCHP. It could release assembly/test capacity currently diverted toward AI customers, helping MCHP serve industrial and other constrained lines. But a sharp capex retrenchment would also threaten the ramp of its data-center products. The asserted resilience of design wins is not proof of durable volumes, and the 24 Gen 6 wins are a multi-quarter conversion story, not current earnings protection.

Near term, guidance embeds a sequential margin reset after nonrecurring, high-margin revenue; the more important risk is whether rising input costs can be absorbed without further margin erosion. Over 1–3 months, watch March-quarter backlog conversion, OSAT qualification progress, and supplier-cost pass-through. Over 6–18 months, industrial recovery and Gen 6 production could broaden growth, while elevated leverage argues against assuming near-term buybacks. Falsifiers: continued backlog growth without shipments, gross margin remaining below the 65% long-term model as costs rise, or evidence that AI customer spending is weakening enough to cancel or materially defer MCHP program ramps.

Key Decisions for Investors

• Avoid extrapolating September-quarter EPS or gross margin: the 100%-margin items do not recur, and the next-quarter guide already reflects both mix normalization and capacity pressure.
• Treat MCHP as a conditional relative-value long versus more AI-concentrated semiconductor exposure if OSAT capacity begins to free up and March/June shipments convert backlog. Do not initiate solely on design-win counts; confirm improving shipments and margin first.
• Track quarterly backlog-to-revenue conversion, lead times, inventory days, underutilization charges, and gross margin against 65%. Persistent backlog growth without shipment acceleration, or further margin deterioration from supplier pricing, invalidates the recovery thesis.
• Keep capital-return expectations modest until leverage declines further; management has indicated debt reduction takes priority over increasing the dividend or resuming repurchases.